

Tirzepatide in Obesity and Pre-Diabetes

Key Takeaways

- ▶ In SURMOUNT-1, patients took tirzepatide for over 3 years
- ▶ About 1,000 people who enrolled had pre-diabetes
- ▶ The risk of progressing to T2D was reduced – about 94% less on tirzepatide than in people receiving placebo
- ▶ Tirzepatide has a different MoA to semaglutide – it is a dual rather than mono-agonist, targeting GIP as well as GLP-1
- ▶ These agents offer a potential change in the management of cardiometabolic disease – treating weight before problems develop

GIP, glucose-dependent insulintropic polypeptide; GLP-1, glucagon-like peptide-1; MoA, mechanism of action; T2D, type 2 diabetes

Source: Aronne L. Interview: Tirzepatide in Obesity and Pre-Diabetes. [The Best of Obesity Week. November, 2024.](#)